Susquehanna International Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-21,500
| Closed | -$88K | – | 10340 |
|
|
2017
Q3 | $88K | Buy |
21,500
+5,500
| +34% | +$21K | ﹤0.01% | 8401 |
|
|
2017
Q2 | $59K | Buy |
+16,000
| New | +$63.5K | ﹤0.01% | 8861 |
|
|
2017
Q1 | – | Sell |
-14,800
| Closed | -$64K | – | 10657 |
|
|
2016
Q4 | $64K | Buy |
+14,800
| New | +$95.7K | ﹤0.01% | 9228 |
|
|
2016
Q3 | – | Sell |
-4,950
| Closed | -$28K | – | 9457 |
|
|
2016
Q2 | $28K | Sell |
4,950
-1,617
| -25% | -$11K | ﹤0.01% | 8340 |
|
|
2016
Q1 | $50K | Sell |
6,567
-2,600
| -28% | -$20K | ﹤0.01% | 8666 |
|
|
2015
Q4 | $122K | Buy |
9,167
+1,650
| +22% | +$28.4K | ﹤0.01% | 8786 |
|
|
2015
Q3 | $124K | Sell |
7,517
-39,483
| -84% | -$809K | ﹤0.01% | 9031 |
|
|
2015
Q2 | $1.05M | Buy |
47,000
+41,200
| +710% | +$652K | ﹤0.01% | 6116 |
|
|
2015
Q1 | $57K | Sell |
5,800
-33
| -0.6% | -$324 | ﹤0.01% | 9128 |
|
|
2014
Q4 | $67K | Buy |
5,833
+316
| +6% | +$3.43K | ﹤0.01% | 9304 |
|
|
2014
Q3 | $64K | Sell |
5,517
-11,333
| -67% | -$173K | ﹤0.01% | 9176 |
|
|
2014
Q2 | $328K | Sell |
16,850
-11,633
| -41% | -$205K | ﹤0.01% | 8229 |
|
|
2014
Q1 | $511K | Sell |
28,483
-10,567
| -27% | -$174K | ﹤0.01% | 6701 |
|
|
2013
Q4 | $412K | Buy |
39,050
+3,533
| +10% | +$39.5K | ﹤0.01% | 7057 |
|
|
2013
Q3 | $439K | Buy |
35,517
+26,750
| +305% | +$282K | ﹤0.01% | 6622 |
|
|
2013
Q2 | $83K | Buy |
+8,767
| New | +$113K | ﹤0.01% | 7855 |
|
Susquehanna International Group's CASC Position: Q1 2018 in Review
Susquehanna International Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 57,192 shares — an estimated $212K sold.
Susquehanna International Group first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $934K in Q1 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Susquehanna International Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 57,192 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $212K.
- Susquehanna International Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 15 quarters.
- Susquehanna International Group's Cascadian Therapeutics, Inc. position peaked at $934K in Q1 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.